> Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Reshma L. Mahtani, DO

Date and Time

Thu, Oct 07, 2021 7:00 pm to 8:00 pm ET

Location

Virtual

Watch session recording

Date and Time

Thu, Oct 07, 2021 7:00 pm to 8:00 pm ET

Location

Virtual

Watch session recording
general_content

Event details

Understanding your breast cancer diagnosis, treatment, and potential side effects can be overwhelming. In this video, Reshma L. Mahtani, DO, answers questions about breast cancer treatment options, recent drug approvals, immunotherapy, as well as symptoms and side effects for early stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer.

video
audio_embed
speakers_feature

About our expert:

Reshma L. Mahtani, DO

Reshma L. Mahtani, DO, is a medical oncologist practicing in South Florida. She is an associate professor of medicine at the University of Miami, Sylvester Comprehensive Cancer Center in Deerfield Beach, Florida. She is co-leader of the breast cancer program and director of community outreach.

Read full bio
upcoming_events

Upcoming Events

Updates from the 2024 San Antonio Breast Cancer Symposium

Tue, Dec 17, 2024

Learn More

Thriving Together: 2025 Conference on Metastatic Breast Cancer

Fri, Mar 07, 2025

Learn More
View All Events View Past Events
related_resources_article_carousel

Related articles

Immunohistochemistry (IHC) tests

11/15/24 | BY: Regina Hampton

Some of the most important breast cancer treatment decisions are based on immunohistochemistry (IHC) tests; hormone receptor status, HER2 status, and in some cases, PD-L1 status.

Read More
 | 7 Min. Read

FISH tests

11/15/24 | BY: Regina Hampton

A FISH test is a lab test performed on tissue taken from a biopsy or breast cancer surgery, that can confirm breast cancer’s HER2 status if other test results are inconclusive.

Read More
 | 5 Min. Read

Targeted therapy for hormone receptor-positive breast cancer

10/14/24 | BY: Sameer Gupta, Pallav K. Mehta

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy, including CDK 4/6 inhibitors.

Read More
 | 12 Min. Read |

Ribociclib

09/18/24 | BY: Sameer Gupta

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More
 | 6 Min. Read |

Early-stage breast cancer trial search

06/21/24

Use this tool to find early-stage breast cancer clinical trials across the United States.

Read More
|

Trastuzumab

05/28/24 | BY: Debu Tripathy

Trastuzumab (Herceptin) is the most common medicine used to treat HER2-positive breast cancer. It is a monoclonal antibody, a medicine made in a lab that attacks a specific protein produced on the outside of a cell.

Read More
 | 12 Min. Read |

HER2-positive or HER2-low

05/28/24 | BY: Pallav K. Mehta

HER2-positive or HER2-low breast cancer is caused by a genetic mutation in the HER2 gene. Learn more about the causes and treatment options for this type of breast cancer.

Read More
 | 14 Min. Read |

Targeted therapy for HER2-positive breast cancer

05/28/24 | BY: Kanu Sharan

Targeted treatments for HER2-positive breast cancer target the HER2 proteins on or within cancer cells that help the cells to grow. They attach to HER2 proteins and block signals that tell the cells to multiply too quickly.

Read More
 | 4 Min. Read |

HER2-Positive MBC

05/24/24 | BY: Pallav K. Mehta

Learn more about metastatic breast cancer that is HER2-positive and how it can be treated with targeted therapy.

Read More
 | 7 Min. Read |

Capivasertib

02/03/24 | BY: Sameer Gupta

Capivasertib (Truqap) is a targeted therapy used to treat hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancers that test positive for certain gene mutations

Read More
 | 9 Min. Read |
stay_connected

Stay Connected

Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.